Development of bi-functional hybrid IgGA antibodies for enhancing cancer immunotherapy
Authors:
- Xiuyun LiXLXiuyun Li
- Vladislav RybchenkoVRVladislav Rybchenko
- Naida MamaevaNMNaida Mamaeva
- Jingyan WangJWJingyan Wang
- Dmitry DolgikhDDDmitry Dolgikh
- Baohang LinBLBaohang Lin
- Victoria ArgentovaVAVictoria Argentova
Open Access
- 4 October 2026
- journal article
- Published by Elsevier in Clinical Immunology
- Vol. 288
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Fcγ receptors and immunomodulatory antibodies in cancerNature Reviews Cancer, 2023
- Neutrophils as immune effector cells in antibody therapy in cancerImmunological Reviews, 2022
- Serum IgA Fc effector functions in infectious disease and cancerImmunology & Cell Biology, 2020
- Neutrophils Kill Antibody-Opsonized Cancer Cells by TrogoptosisCell Reports, 2018
- IgGA: A “Cross-Isotype” Engineered Human Fc Antibody Domain that Displays Both IgG-like and IgA-like Effector FunctionsChemistry & Biology, 2014
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- The Basic Principles of Chimeric Antigen Receptor DesignCancer Discovery, 2013
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityJournal of Experimental Medicine, 2010
- A General Framework for Development and Data Analysis of Competitive High-Throughput Screens for Small-Molecule Inhibitors of Protein−Protein Interactions by Fluorescence PolarizationBiochemistry, 2004
- IgA antibodies for cancer therapyCritical Reviews in Oncology/Hematology, 2001